Explainer · September 2026. Educational only—not medical advice. Compounded medications are not FDA-approved.
Disclosure: We may have a financial affiliation with entities here. We are an independent educational publisher.
In July 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) recommended six 503A bulk substances: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon; it voted against DSIP.
What it means
PCAC advises FDA; it does not approve drugs or legalize compounding. FDA still must decide. Category 2 removal after withdrawn nominations does not place a substance in Category 1 or make it safe to compound and advertise. Coverage reported FDA scientific staff opposed all seven; industry-tie reports are context, not audited findings.
Six, without hype
BPC-157: preclinical, limited human data, WADA-banned. TB-500: non-approved wellness use. KPV: investigational. MOTS-c: early science. Semax: not FDA-approved. Epitalon: longevity marketing red zone.
None is an FDA-approved disease treatment; compounded versions remain not FDA-approved. Research vials add quality risks, and preclinical signals are not randomized human trials.
Questions
Is a licensed clinician and patient-specific prescription involved? Is there a licensed U.S. 503A/503B pharmacy rather than a research seller? Is “FDA approved” based only on PCAC or Category 2 news? Are cure or guaranteed-outcome claims attached?
Bottom line: PCAC votes are process news, not a finish line. Most wellness peptides remain investigational or unapproved.
Sources: Medscape, BioPharma Dive, ArentFox Schiff, FDA, PubMed Central. © 2026 The Peptide Report.